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Long non-coding RNAs (lncRNAs) show patterns of
tissue- and cell type-specific expression that are
very similar to those of protein coding genes and
consequently have the potential to control stem
and progenitor cell fate decisions along a differentia-
tion trajectory. To understand the roles that lncRNAs
may play in hematopoiesis, we selected a subset of
mouse lncRNAs with potentially relevant expression
patterns and refined our candidate list using evi-
dence of conserved expression in human blood line-
ages. For each candidate, we assessed its possible
role in hematopoietic differentiation in vivo using
competitive transplantation. Our studies identified
two lncRNAs that were required for hematopoiesis.
One of these, Spehd, showed defective multilineage
differentiation, and its silencing yielded common
myeloid progenitors that are deficient in their oxida-
tive phosphorylation pathway. This effort not only
suggests that lncRNAs can contribute to differentia-
tion decisions during hematopoiesis but also pro-
vides a path toward the identification of functional
lncRNAs in other differentiation hierarchies.
INTRODUCTION
Long noncoding RNAs (lncRNAs) can function as regulators of
cell fate via a number of mechanisms, ranging from gene expres-
sion regulation to effects on mRNA and protein stability (Dela´s
and Hannon, 2017). While there are many thousands of lncRNAs
annotated in different genomes (Mele´ and Rinn, 2016), the
challenge of identifying those that regulate a particular process
is still significant. With the breadth of information that the field
has produced on hematopoietic stem cell (HSC) differentiation,
the hematopoietic system is the perfect model to investigate
how lncRNAs regulate differentiation (Orkin and Zon, 2008).
The power of this system hinges on the ability to perform in vivoThis is an open access article undbone marrow reconstitutions, the ultimate proof of biological
relevance.
Regulation of cell fate transitions during hematopoiesis has
been studied at many different levels. Transcription factors
essential for various steps of hematopoietic differentiation (Orkin
and Zon, 2008) are often positive regulators of their own tran-
scription, forming a highly dynamic transcription factor network
(Sch€utte et al., 2016). This tight regulation of gene expression
is also highly dependent on additional transcriptional control
mechanisms, such as DNA methylation changes (Challen et al.,
2011, 2014; Trowbridge et al., 2009) and chromatin modifica-
tions (Kerenyi et al., 2013). Post-transcriptional regulation
through microRNAs has also been described, with the most
notable examples being MicroRNA-126, which promotes HSC
quiescence (Lechman et al., 2012), and miR-223, required for
granulocyte differentiation (Fukao et al., 2007; Johnnidis et al.,
2008).
The function of several lncRNAs has been addressed in in vitro
models of hematopoietic differentiation, such as granulocyte dif-
ferentiation (Zhang et al., 2009), eosinophil differentiation (Wag-
ner et al., 2007), and erythropoiesis (Hu et al., 2011). Global anal-
ysis of annotated lncRNAshas also revealed that their expression
is regulated in early stem cell populations (Cabezas-Wallscheid
et al., 2014). Since the currentGENCODE annotation for lncRNAs
is mostly based on easy-to-culture cell lines or whole organisms,
it lacks many of the cell type-specific hematopoietic transcripts.
Tocircumvent this, somegroupshaveassembledannotations for
subsets of the hematopoietic lineage or for some of the differen-
tiationmodelsmentioned above (Alvarez-Dominguez et al., 2014;
Luo et al., 2015; Paralkar et al., 2014). We recently sought to pro-
duce a robust annotation that encompassed cell types from
HSCs todifferentiated cells, bothmyeloid and lymphoid lineages,
as well as blood cancers (Dela´s et al., 2017). In our first proof-of-
concept study, we used this resource to characterize lncRNAs
required for acute myeloid leukemia (AML).
Here, we focused on characterizing lncRNAs involved in the
earliest choices the HSC must make: self-renewal or commit-
ment to a lineage. To address this question, we devised an
experimental strategy whereby long-term reconstituting HSCs
could be transduced in vitro with short hairpin RNAs (shRNAs)Cell Reports 27, 719–729, April 16, 2019 ª 2019 The Authors. 719
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. An Approach to Enrich Potentially Functional lncRNAs
(A) Pipeline overview from the expression patterns selected to mouse-human expression correlation.
(B) Expression heatmap of the 45 mouse lncRNAs that have expressed syntelogs in humans, indicating their level of expression correlation and the lncRNAs
selected for in vivo studies.
(C and D) Genome browser plots for the mouse (left) and human (right) loci for lnc11833-AC002454.1 (C) and lnc6689/2810468N07Rik-RP11-161M6.2 (D).
See also Figure S1 and Table S1.targeting lncRNAs and then transplanted to uncover lncRNA
dependencies in vivo. Since many aspects of hematopoiesis
are conserved between mice and humans (Shay et al., 2013),
we reasoned that if we could identify lncRNAs with syntenic con-
servation and conserved expression in humans, then we could
enrich for functional potential.
RESULTS
Combination of Differential Expression with Syntenic
Conservation and Conserved Expression to Enrich
Functional lncRNAs
Wehypothesized that if the expressionof acandidate lncRNAwas
tightly regulated during hematopoietic differentiation, then it
would be more likely to be involved in regulating cell fate transi-720 Cell Reports 27, 719–729, April 16, 2019tions thanwould aubiquitously expressed transcript. Tomaximize
the likelihood of identifying lncRNAs functionally required for HSC
differentiation and/or self-renewal, we used expression analysis
and combined lncRNA annotations with (1) enriched expression
in HSCs, committed myeloid or granulocyte-monocyte (CMP/
GMP), or lymphoid progenitors (CLP) when we analyzed differen-
tial expression between those cell types (progenitor cell type en-
riched); (2) differential expression between myeloid and lymphoid
lineages that already displayed primed differential expression
at theprogenitor level (lineage enriched); and (3) differential down-
regulation during differentiation while already differentially ex-
pressed between any of the progenitor or stem populations
(downregulated in differentiation) (Figure 1A). This generated a
list of 295 mouse lncRNAs with suggestive expression patterns
(Figure S1A).
lncRNAs are often not conserved in sequence, but one can
often find an lncRNA in a syntenic position in different genomes
(Hezroni et al., 2015). We found that in 97 cases, we could iden-
tify an annotated lncRNA in a syntenic position in the human
genome. We then selected lncRNAs expressed in human cord
blood HSC, CMP, GMP, and CLP (Chen et al., 2014), yielding a
list of 45 lncRNAs.
We analyzed the expression correlation for each of these
lncRNAs in humans and mice for the aforementioned cell types
to prioritize lncRNAs for in vivo studies. Due to limitations in
lncRNA assemblies and the complex genomic organization of
some loci, we assembled our final list of five lncRNAs after
manual inspection of each genomic locus to ensure that the hu-
man expression data were reflective of the lncRNA levels (and
not an overlapping gene) and that the lncRNAs selected showed
a consistent exon structure across replicates (Figures 1B–1D
and S1B–S1D; Table S1).
lnc11833, for example, is divergently transcribed with Cdk6
and dramatically upregulated in all committed progenitors as
compared to stem cells in both mice and humans (Figure 1C).
Given the reported role of Cdk6 in regulating human HSC quies-
cence (Laurenti et al., 2015), the location and expression of
this lncRNAwas potentially suggestive of an effect in cis. Another
lncRNA, lnc6689, is expressed in HSCs but not in the progen-
itor cell types (Figure 1D). While lnc6689 (2810468N07Rik in
GENCODE) is also expressed divergently from a neighboring
protein-coding gene, Sox8, this gene is not expressed in blood
progenitors and does not have any known role in hematopoiesis.
We also identified an already described lncRNA that overlaps
with miR-223 (lnc15847, F630028O10Rik) (Figure S1B). This
microRNA plays a role in myelopoiesis (Fazi et al., 2007; Fukao
et al., 2007), and the lncRNA has recently been implicated in
AML (Mangiavacchi et al., 2016).
Bone Marrow Transplantation Identifies lncRNAs
Required for Hematopoiesis In Vivo
To assess the functional importance of our selected lncRNAs
in vivo, we performed bone marrow reconstitutions, transplant-
ing HSCs transduced with an shRNA against the lncRNAs.
shRNAs were designed with our previously published algorithm
for the prediction of highly potent shRNAs (Knott et al., 2014) and
cloned into a constitutive lentiviral vector where a spleen focus-
forming virus (SFFV) promoter drives the expression of a green
fluorescent protein (zsGreen) and an shRNA. Sorted CD45.2
E-SLAM (CD45+/EPCR+/CD48–/CD150+) HSCs (Kent et al.,
2009) were transduced with high titer lentivirus for 20 h before
injecting them into irradiated recipient CD45.1 animals. The cells
were mixed with competitor CD45.1 whole bone marrow before
injection. Peripheral blood was analyzed starting at 4 weeks
post-transplant (Figures 2A and S2A). Because only a fraction
of HSCs transplanted had been transduced, we monitored the
zsGreen percentage within the donor compartment over time
as a phenotypic readout. If the shRNA and zsGreen-expressing
cells were less able to repopulate the hematopoietic compart-
ment as compared to the non-transduced counterparts, then
we would expect a depletion of zsGreen+ cells over time.
We saw a dramatic decrease in the representation of zsGreen+
cells transduced with an shRNA against positive control Spi1(also known as PU1) as compared to cells expressing an shRNA
against our negative control, Renilla luciferase (Figure 2B). Spi1
is a transcriptional activator that is indispensable for HSC self-
renewal and commitment to and maturation of myeloid and
lymphoid lineages (Iwasaki et al., 2005). We therefore would
expect almost no output of differentiated cells from HSCs in
which Spi1 was silenced. Of note, because we do not have a
robust way of measuring initial HSC infection rates (many
animals would be required to measure the initial infection of
this very rare population), we normalize to the initial blood
measurement at 4 weeks post-transplant. By that point, the per-
centage of zsGreen-expressing cells could already be greatly
reduced if the targeted RNA were required for HSC differentia-
tion or maintenance.
Using this readout, we identified lnc12928 as our strongest
candidate. Using two independent shRNAs, we saw between
4- and 8-fold average reduction in the relative number of
zsGreen+ cells within the donor compartment during the course
of the experiment (Figures 2B and S2B). To verify that we were
affecting the expression of the targeted lncRNAs with our
shRNAs, we performed a knockdown analysis on cell lines that
express each of the targeted lncRNAs. Using this approach,
we confirmed that the levels of lnc12928 were greatly reduced
using both shRNAs and when measured with two independent
primer pairs (Figure 2B).
We noticed that the only shRNA that successfully silenced
lnc11833 was also the only one that gave rise to a depletion
of zsGreen-expressing cells in vivo (Figures 2B and S2B).
This suggests that lnc11833 could still be an important lncRNA
in hematopoiesis, although additional lncRNA depletion ex-
periments with other tools would be required to validate this
observation.
These results show that our HSC transduction followed by
transplantation approach is a useful way to identify the genes
that are required for hematopoietic reconstitution in general,
and is a powerful tool to identify functional lncRNAs.
HSCs Depleted of lnc6689 Display a Lineage-Bias
Phenotype
lncRNAs could affect hematopoiesis in a variety of ways that
would not necessarily lead to changes in the overall representa-
tion of zsGreen+ cells. For example, our lineage control in this
assay is early B cell factor 1 (Ebf1), a gene required for B cell dif-
ferentiation (Zandi et al., 2008). Ebf1 knockdown does not result
in changes in the relative fraction of zsGreen+ cells, as compared
to week 4 post-transplant (Figure 2B). However, we observed
that within each animal, the percentage of zsGreen+ cells in the
B220+ compartment was much lower than in the myeloid cell
types (Figure S2C). To investigate this further, we assessed the
percentage of zsGreen+ cells within the B cell donor compart-
ment relative to the overall zsGreen+ population derived from
the donor (lineage bias), and performed the same analysis for
the myeloid lineage (Figures 2C, S2B, and S2C). This showed a
clear bias against the B lineage and enrichment of the myeloid
compartment for Ebf1 knockdown (Figure 2D). Renilla shRNAs,
in contrast, showed a generally balanced phenotype, where
the fraction of zsGreen+ cells within each lineage mirrored the
representation of zsGreen+ populations in blood overall.Cell Reports 27, 719–729, April 16, 2019 721
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Figure 2. In Vivo Reconstitution with lncRNA-Depleted HSCs Identifies lncRNAs Involved in Overall Differentiation or Lineage Specification
(A) Schematic representation of the vector used and the experimental design. NeoR, neomycin resistance gene. WBM, whole bone marrow.
(B) Heatmap depicting the average depletion of zsGreen+ cells relative to the week 4 measurement (left) and the corresponding level of knockdown in a cell line
that expresses the corresponding lncRNA (see STAR Methods) for each shRNA assayed in vivo (right). N is the number of mice analyzed for each knockdown.
Black boxes represent significantly depleted time points (p < 0.05; Mann-Whitney test).
(C) Schematic representation of the concept of lineage bias analysis.
(D) Average lineage bias for the myeloid and B lineages at the different time points in the blood for the indicated knockdowns. The error bars represent SEMs. The
raw data from this analysis are the same as in (B). *p < 0.05; Mann-Whitney test.
See also Figure S2.By performing the same lineage-bias analysis, we found that
one of our lncRNAs, lnc6689, had a potential bias against B cells
or in favor of the myeloid lineage (Figures 2D and S2C). We see
this phenotype with both shRNAs targeting this lncRNA,
although the extent of the effect differs. This indicated that
each zsGreen-expressing HSC transplanted is producing fewer
B220+ progeny or more myeloid cells. The extent of this pheno-
type correlated with the degree of knockdown we observed
when this lncRNA was targeted in A20 cells (Figures 2B and
S2B), suggesting a dose-dependent effect.
While lnc6689 has striking HSC-specific expression among
progenitor cell types (Figure 1D), we also observed its presence
in pre- and pro-B cells (Figure S3A), which means that the line-
age-biased phenotype could be mediated either by its func-
tioning in HSCs or via an effect during B cell differentiation.
To establish a strategy in which we could address potential
cell type-specific effects, we built an inducible shRNA vector
that would allow us to perform bone marrow reconstitutions722 Cell Reports 27, 719–729, April 16, 2019and only activate shRNA expression once the hematopoietic
system has been repopulated. With this approach we could
acutely induce an shRNA and investigate its impact in different
cell types or at different time points (Figure 3).
We transduced cells with inducible shRNAs against lnc6689
or controls, Renilla and Ebf1, and transplanted them into
cKit(w41);CD45.1, a mouse strain that is particularly suitable as
an HSC recipient and that only requires sublethal irradiation.
We allowed the animals to reconstitute and induced the shRNA
by feeding doxycycline-containing food (Figure 3A). When we
looked at the whole bone marrow (after lysing red blood cells)
of these animals, we saw a bias against the B220+ compartment
for cells in which Ebf1, our lineage control, was silenced, with
no change in the myeloid compartment, which constitutes
the largemajority of the non-progenitor cells in the bonemarrow.
The extent of the bias increased in magnitude if we adminis-
tered doxycycline to the animals for 6 days rather than 2 days
(Figure 3B), but it is not statistically significant in either case.
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Although we also see a bias against the B220+ compartment in
the lnc6689 knockdown, the phenotype is less severe and quite
variable, especially with shRNA 4 (Figure 3B). Additional experi-
mental efforts with different depletion tools and at later time
points will be required to further validate this phenotype and
the role of lnc6689 in either stem cells or the B cell compartment
directly. For these reasons, we decided to focus our attention on
lnc12928.
lnc12928 (Spehd) Is Required for Hematopoiesis during
Regeneration and in Homeostasis Post-transplantation
Using the same inducible system described above, we sought to
investigate whether the lnc12928 requirement we noted in ani-
mals during reconstitution was also observed if the knockdown
was induced after the hematopoietic system had recovered
following transplantation. We found that the representation of
zsGreen+ cells within the donor compartment decreased over
time in the peripheral blood of animals transplanted with HSCs
with lnc12928 knockdown, compared to the initial percentage
2 days post-administration of doxycycline (Figures 3C, S3B,
and S3C). For shRNA 20, the effect of the depletion is similar
to that of the positive control knockdown, Spi1 (PU1), which is
known to be essential in HSCs (Figure 3C).
This confirms that lnc12928 is required for hematopoiesis,
both in the setting of reconstitution and for homeostasis post-
transplant. This lncRNA is highly enriched in hematopoietic
progenitors, but not in any of the differentiated cell types (Fig-
ure S3A). Consequently, these data suggest that this lncRNA
must exert an effect at the level of the stem and/or progenitor
cell types. We therefore named this lncRNA Spehd (stem and
progenitor enriched required for hematopoietic differentiation).
The predicted ‘‘lncRNA locus’’ (i.e., the collection of all of the
possible isoforms) in our catalog extended upstream of the
area where we observed strong RNA sequencing (RNA-seq)
coverage in our cell types to the start of its upstream gene,
Gata2 (Figure S1). This predicted locus would overlap with a
known Gata2 enhancer at 1.8 kb (Snow et al., 2010) (Figures
3G and 3H). To better characterize this lncRNA, we performed
30 and 50 rapid amplification of cDNA ends (RACE) in AML cells,
which was further validated with lineage-depleted bone marrowFigure 3. lnc6689KnockdownResults in BCell Depletion andMyeloid E
(A) Schematic representation of the vector used and the experimental design for
(B) Lineage-bias values for the B and myeloid lineages in the bone marrow for the
center of the box indicates average and the box edges represent SEM.
(C) Proportion of zsGreen+ cells within donor peripheral blood relative to 2 days p
average and SEM presented for each time point). For the last time point (50 da
indicates average and the box edges represent SEM. *p < 0.05; Welch’s unequa
(D) Schematic representation of the vector used and the experimental design for
(E) Representative flow cytometry plots of the peripheral blood of animals transpl
analyzed.
(F) zsGreen donor percentage for each re-transplanted animal at 3 weeks post-t
dition; the error bars represent SEMs. *p < 0.05; Welch’s unequal variances t tes
(G) Genome browser representation of the predicted lnc12928 locus and its neighb
indicated. Gata2 chromatin immunoprecipitation sequencing (ChIP-seq) tracks a
(H) Magnified region as indicated in (G), showing the RNA-seq coverage for long
(I) Magnified region as indicated in (H), showing the transcript starts and ends, as
indicated. The assay for transposase accessible chromatin with high-throughput s
shRNAs used against this lncRNA are also presented. Lin, lineage.
See also Figure S3.
724 Cell Reports 27, 719–729, April 16, 2019cells. This confirmed that the lncRNA start and termination sites
flanked the area of high RNA-seq coverage, where our shRNAs
weredesigned (Figure 3I). Previously publishedDNAaccessibility
data (Lara-Astiaso et al., 2014) further support start site location.
Regarding the structure of the lncRNA, only 3 of 21 cDNA Sanger
sequencing reads that would span the predicted first intron and 0
of 43 that covered the second showed evidence of splicing (data
not shown). This would suggest that the predominant isoform is
not spliced, which would be in line with the RNA-seq coverage,
although a much larger number of reads would be required to
confidently estimate isoform abundances. These RACE data
also exclude any genomic overlap between Spehd and another
previously described Gata2 enhancer at 77 kb (Grass et al.,
2006) (Figure 3G).
Depletion of Spehd Results in Impaired Stem and/or
Progenitor Contribution to Hematopoiesis
We next isolated shRNA-expressing cells that we could trans-
plant into recipient animals as the sole source of donor cells.
Since we expected that for some of the knockdowns these cells
would have a deleterious reconstitution phenotype, we used the
same competitive transplantation setup as our initial studies
(Figure 2A), using C57BL/6-CD45.1 as recipients and co-inject-
ing whole bone marrow from CD45.1 littermates. To isolate the
zsGreen-expressing cells, we kept the primary transplanted an-
imals on doxycycline food for 2 days before bonemarrow extrac-
tion. The recipient animals were similarly kept on doxycycline
food to maintain shRNA expression. Due to the extremely low
numbers of HSCs in each animal and the fact that the zsGreen+
cells are only a subset of the donor compartment, we sorted
zsGreen+ LSK (Lineage Sca1+ cKit+), which contains a number
of multipotent progenitors, in addition to HSCs (Figure 3D).
We transplanted 3,000 zsGreen-expressing LSK cells into
each animal, together with a competitive dose of CD45.1 whole
bone marrow. At week 3 post-reconstitution, we analyzed the
peripheral blood for donor contributions resulting from negative
control (Renilla), Spehd, or positive control (Spi1) knockdown.
Whereas the contribution from the Renilla-knockdown cells
reached 25% of nucleated peripheral blood, the ability of LSK
cells to reconstitute the animals when depleted of Spehd wasnrichment, while lnc12928 Is Required forMultilineageDifferentiation
bone marrow transplants using inducible shRNAs.
knockdowns indicated in animals induced with doxycycline for 2 or 6 days. The
ost-administration of doxycycline for each shRNA over time (left [days on dox],
ys), the values for each animal are represented (right). The center of the box
l variances t test.
re-transplantations.
anted solely with zsGreen+ LSK, as described in (D), for each of the conditions
ransplant. The bar heights indicate the average zsGreen percentage per con-
t.
oring genesGata2 andRpn1. The location of the publishedGata2 enhancers is
re displayed as obtained from codex.stemcells.cam.ac.uk.
-term HSC (LT-HSC).
defined by 50/30 RACE. The RNA-seq coverage is presented for the cell types
equencing (ATAC-seq) came from Lara-Astiaso et al. (2014). The location of the
reduced to 10% on average, and as little as 5% in some
animals (Figures 3E and 3F). Although all of the cells in the donor
compartment should be zsGreen+, we saw a fraction of the
donor being zsGreen (presumably due to silencing of the inte-
grated cassette) (Figure S3D). This donor-derived zsGreen
fraction is especially prominent in cells carrying Spehd shRNA
20 or Spi1 shRNA 1, when the cells that managed to silence
the transgene could have the greatest advantage (Figure S3D).
The effects are also seen if we look within each lineage for
monocyte-macrophages and granulocytes and are apparent
already at 3 weeks post-transplant (when the donor cells have
not yet contributed to the B compartment) (Figures S3B and
S3D). These data support an essential role for Spehd during
HSC and/or progenitor cell self-renewal or differentiation that
leads to impaired hematopoiesis when the lncRNA is depleted.
Because we transplanted LSK, which encompasses both
HSCs and multipotent progenitors, we are unable to identify
the specific cell type affected to cause this depletion. The
zsGreen contribution at later time points (up to week 9) was
very low, even for the Renilla sh control, indicating a very small
proportion of long-term reconstituting HSCs within the cell pop-
ulation transplanted into these animals. This, again, precludes us
from distinguishing defects in the stem versus the progenitor
compartment.
The CMP Compartment Shows Defects in Respiratory
Pathways when Spehd Is Depleted
To investigate the earliest consequence of Spehd knockdown
and the cell types that are most affected by its depletion, we iso-
lated cells from animals that had been reconstituted with shRNA-
inducible HSCs and administered doxycycline for 6 days. When
we examined genes that were differentially expressed upon
lncRNA knockdown versus control CMPs, we identified 426
genes that were consistently downregulated upon suppression
of the lncRNA (false discovery rate [FDR] <0.05). Those genes
were strongly enriched for components of the oxidative phos-
phorylation pathway (Figure 4A). The signature is driven by 43
genes (Figure S4A) that are downregulated in CMPs (lncRNA
knockdown versus control), but to a much lesser extent or not
consistently affected in LSK (a stem and progenitor compart-
ment that includes the HSCs) (Figures 4B and S4B). While the
pathways enriched among the upregulated genes (Figure 4A)
warrant further investigation, we chose to focus on the oxidative
phosphorylation signature, given that 33% of the genes anno-
tated for this pathway in the Kyoto Encyclopedia of Genes and
Genomes (KEGG) were downregulated (43/130 genes annotated
in the pathway).
HSCs are reported to primarily use glycolysis (Takubo et al.,
2013) and have a lower respiratory capacity than multipotent
or committed progenitors (de Almeida et al., 2017). Moreover,
several mutants with mitochondrial and respiration defects
have profound hematopoietic defects (Maryanovich et al.,
2015; Yu et al., 2013), andHSCswith lowermitochondrial activity
have a greater reconstitution capacity (Vannini et al., 2016).
Therefore, it seemed possible that cells with a reduced expres-
sion of genes encoding respiratory chain components could
encounter a roadblock when their metabolic requirements in-
crease during their commitment to differentiation and expansion.We therefore askedwhether the 43 oxidative phosphorylation-
pathway genes affected in CMP following Spehd depletion
showed an increase in expression during the differentiation be-
tween LSK and CMP. In the Renilla control, all of the genes
show, on average, increased expression, and 29 of the 43 are
significantly upregulated (FDR <0.05). Consistent with our previ-
ous analysis, these genes fail to become induced in the CMPs
depleted of lncRNA Spehd (Figure S4B). These results indicate
a defect in the CMP population, which fails to activate the oxida-
tive phosphorylation pathway genes and could partly explain
the substantial reduction in differentiated cell output that we
observed in this lncRNA knockdown.
Spehd was primarily cytoplasmic in AML cells as measured
both byRT-qPCR following subcellular fractionation (Figure S4C)
and single-molecule fluorescence in situ hybridization (FISH)
(Figures S4D and S4E). We further validated the specificity of
the single-molecule FISH by analyzing the number of molecules
upon Spehd knockdown (Figures S4F and S4H). While the exact
mechanism by which Spehd exerts its function remains to be
elucidated, its localization would seem to exclude direct effects
at the transcriptional level. This fits with the observation that the
oxidative phosphorylation genes affected include three mito-
chondrially transcribed genes (Figure S4A, gene names in
bold). Taking advantage of the RNA-seq data produced, we
also examined the potential effects on the genes neighboring
lnc12928/Spehd. For the well-known hematopoietic regulator
Gata2, we observed a slight (on average, 15%) reduction, with
both shRNAs against Spehd in CMPs (data not shown). While
we cannot exclude that this plays a role in the phenotype, further
experiments would be required to address whether such a
modest change could have the impact that we observe.
To further investigate thedeficiencies observed in theoxidative
phosphorylation pathway, we transplanted animals following the
same experimental design used for transcriptomic profiling (Fig-
ure 4A). We tested whether mitochondria function was affected
by lncRNA knockdown in the common myeloid progenitor using
tetramethylrhodaminemethyl ester (TMRM). This cell-permeable
dye is sequestered in active mitochondria and gives a progres-
sively higher readout as the cells progress down the hematopoi-
etic lineage to more committed states (Vannini et al., 2016) (Fig-
ure 4C). When we measured the relative TMRM levels for CMPs
(see STAR Methods), we saw, on average, a reduction in the
TMRM signal for both shRNAs targeting Spehd after doxycycline
administration for 6 days (Figures 4Dand 4E).While both shRNAs
show the same trend, shRNA 20 provokes once again a stronger
phenotype and is the only one to reach statistical significance.
We note that TMRM accumulation could also correlate with
bulkmitochondrialmass rather than theirmetabolic capacity. An-
imals analyzed after 13 days on doxycycline showed a depletion
of relative TMRM levels in the LSK compartment (Figure 4E). This
could be a downstream effect from a deficiency in CMPs, or it is
possible that the LSK compartment would eventually show the
same transcriptional deficiency in oxidative phosphorylation at
later time points. No significant changes are observed in the
megakaryocyte-erythroid progenitor (MEP) or GMP populations
(Figure S4H). Determining the bone marrow cell types being
depleted or blocked in their differentiation potential will be essen-
tial to fully understand the function of this lncRNA.Cell Reports 27, 719–729, April 16, 2019 725
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Figure 4. Depletion of lnc12928 Results in Deficient Mitochondrial Function in Myeloid Progenitors
(A) Heatmap of all of the differentially expressed genes (FDR < 0.05, DESeq) between Spehd and Renilla knockdown in CMP (left) and the results of functional
annotation analysis (right).
(B) Fold change for each shRNA against the lncRNA relative to Renilla in CMP and LSK for the genes in the oxidative phosphorylation pathway (KEGG) differ-
entially expressed in CMP. Box and whiskers plots show the distribution of all of the genes represented. Boxplots correspond to themedian and the 25th and 75th
percentiles. The whiskers extend to the largest values, but no further than 1.5, the interquartile range (distance between the first and third quartiles), in which case
the outliers are shown.
(C) Representative flow cytometry plots showing the gating strategy for long-term (LT) and short-term (ST) repopulating HSCs (out of LinSca1+ cKit+) and CMPs,
GMPs, and MEPs (out of Lin Sca1 cKit+), and the corresponding distribution of the TMRM intensity for each population.
(D) Representative flow cytometry plots of the TMRM of CMP and the TMRM in all of the progenitors and stem cells for Renilla shRNA and shRNA 20 against
lnc12928.
(E) TMRM (geometric mean) in CMP or LSK relative to overall TMRM in the sample (in all of the progenitors and stem cells) per animal. The box represents average
and SEM. *p < 0.05; Mann-Whitney test.
See also Figure S4.
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Ourworking hypothesis is that theability of thesedefective pro-
genitors to differentiate is reduced, leading to the strong pheno-
typewe consistently observed. Follow-up studieswill be required
to determine whether these cell types are being depleted them-
selves or accumulate in the bone marrow. In addition, B cells
were also greatly reduced when this lncRNA was knocked
down (FigureS3C), andwesuspect that a similar phenotypecould
be occurring in the lymphoid compartment at an unexplored time
point, although an alternative mechanism that explains the
lymphoid deficiency could also be contemplated.
DISCUSSION
We have previously cataloged lncRNA expression during mouse
hematopoiesis and carried out a functional analysis of lncRNAs
in the hematopoietic compartment in mouse leukemias as a
proof of concept (Dela´s et al., 2017). Here, we have further
explored lncRNA function in hematopoiesis, developing a strat-
egy that allowed us to identify lncRNAs that play a role in HSC
self-renewal or differentiation. Studies of HSCs pose many
challenges because of their very low abundance and the lack
of culture conditions that are suitable for their expansion. This
prompted us to attempt to examine lncRNA function using in vivo
HSC reconstitutions. While it is a powerful approach, the number
of candidates that can be assessed using such assays is much
lower than one can survey in vitro.
The strategy that we developed for candidate selection nar-
rowed our study to five lncRNAs and was aimed at identifying
non-coding species that could regulate the first steps of HSC
commitment into myeloid or lymphoid lineages. However, this
combination of differential expression, synteny, and conserved
expression is broadly applicable to either other cell types in the
hematopoietic lineage or other tissues.
Within the final candidate list, we noted that many of the genes
surrounding the lncRNAs of interest had known roles in hemato-
poiesis (e.g., Cdk6, Gata2). Although a conserved role in cis
cannot be excluded, we suspect that these coding and non-cod-
ing genes are simply regulated by the same tissue-specific ele-
ments in both mice and humans, which allows them to fulfill
criteria that we set for candidate selection. One major drawback
of our selection strategy was that we could have missed a func-
tionally conserved lncRNA that does not show synteny between
mice and humans.
Spehd emerged from this approach as an lncRNA required for
stem cell differentiation. HSCs with reduced levels of Spehd
show a decreased capacity for multilineage differentiation over
time via either an HSC defect or a broad effect on all progenitors.
Further transcriptomic analysis showed that this defect could, in
part, be due to deficient oxidative phosphorylation in the CMP
population. Even a slight defect in this pathway has the potential
to be detrimental during a process in which cells exit a quiescent
state andmust undergo a rapid expansion, giving rise to amyriad
of differentiated cell types. A recent report has identified the
lncRNA here annotated as lnc6689 (2810468N07Rik) also as be-
ing a regulator of oxidative phosphorylation in a microRNA-
dependent manner (Sirey et al., 2018). Of course, the major
questions that remain are a challenge in lncRNA biology more
broadly—by what mechanism precisely does this non-codingRNA regulate the differentiation potential and the metabolic ca-
pacity of HSCs.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
Bonemarrow transplantations ofmodifiedHSCs and subsequent analysis of peripheral blood and bonemarrow from thesemicewere
performedat theCancerResearchUKCambridge Institute (Cambridge,UK). FemaleC57BL6JandC57BL/6-CD45.1werepurchasedCell Reports 27, 719–729.e1–e6, April 16, 2019 e2
from Charles River (Kent, England) and used for tissue extraction (donor; C57BL6J) or as bone marrow transplant recipient (C57BL/
6-CD45.1) at 9–12 weeks old. C57BL/6-CD45.1 whole bone marrow used in competitive transplants was obtained from female litter-
mates to the recipient animals.C57BL/6-CD45.1; cKit-w41animalswere re-derived fromembryosprovidedbyDavidKent at theCam-
bridge Institute for Medical Research. Both female and male were used as recipients in inducible transplantations at 9–12 weeks old.
Induction of shRNAs was performed by administering doxycycline-containing food (625 mg/kg) for the days indicated at 10 weeks
(Figure 3B and Figure 4A) or 12-13 weeks (Figure 3C, Figure 4D-E) post-transplant. These animal procedures were conducted in
accordance with project and personal licenses issued under the United Kingdom Animals (Scientific Procedures) Act, 1986.
Cell lines
MLL-AF9;NRASG12D AML cells were obtained from the Lowe laboratory (Zuber et al., 2011) and cultured in RPMI-1640with GlutaMax
(GIBCO), supplemented with 10% heat-inactivated FBS (GIBCO) and 1% Penicillin/Streptomycin (GIBCO) under 7.5% CO2 culture
conditions. This leukemia model was generated from fetal liver cells and the cell line established from it, also known as RN2, is of
unspecified sex. A20 cells (sex unspecified, purchased from ATCC) were cultured in RPMI-1640 ATCC modification (GIBCO),
supplemented with 10% heat-inactivated FBS (GIBCO), 1% Penicillin/Streptomycin (GIBCO), and 0.05 mM b–mercaptoethanol
(GIBCO). 293FT cells (purchased from Thermo Fisher Scientific) were cultured as per manufacturer’s instructions. All cell lines tested
negative for mycoplasma contamination by RNA-capture ELISA.
METHOD DETAILS
lncRNA candidate selection
The mouse RNaseq libraries from progenitors and differentiated cell types were previously published (Dela´s et al., 2017). Differential
expression among hematopoietic progenitors was analyzed using DESeq2 (Love et al., 2014) and lncRNAs were considered to be
differentially expressed if the fold change exceeded 2 and FDR < 0.05 in the comparisons indicated in the main text. Synteny was
determined by converting the genomic interval for themouse lncRNAs of interest from themm10 to hg38 assembly using the UCSC’s
liftover tool. The presence of human lncRNAs in these regions was verified using ‘‘BEDTools Intersect’’ with the GENCODE v22
lncRNA annotation. Human RNaseq expression data from cord progenitor types was obtained from previously existing datasets
(Chen et al., 2014). Reads were mapped with the STAR aligner (Dobin et al., 2013) against the hg38 assembly, and fragment counting
was performed with htseq-count (Anders et al., 2015). To compute expression correlation between mouse and human we first
selected lncRNAs with an average expression across the human cell types of more than 20 normalized counts (value determined
from the empirical count distributions). DESeq2 was used to calculate variance-stabilized data for each cell type in human and
mouse. Expression correlation was computed between the median values for HSC, CMP, GMP and CLP in mouse versus human
using Pearson correlation.
shRNAs design and cloning
shRNAs were predicted using the shERWOOD computation algorithm (Knott et al., 2014) as previously described for lncRNAs (Dela´s
et al., 2017). shRNAs were cloned into the appropriate vectors, with ultramiR backbone: ZIP-Neo (constitutive bone marrow trans-
plantations), or T3G-zsGreen-ultramiR-SFFV-rtTA (L3zUSR) (clonal inducible cell lines, inducible bone marrow transplantations) as
previously described (Knott et al., 2014).
Virus production
In brief, virus was prepared in 15 cm dishes using 293FT cells (Thermo Fisher Scientific). The transfection mixture contained 32 mg of
DNA vector, 12.5 mg of pMDL, 6.25 mg of CMV-Rev, 9 mg of VSV-G, 200 mg of Pasha siRNA (QIAGEN Custom siRNA CGGGTGGAT-
CATGACATTCCA, QIAGEN), 125 ml 2.5M of CaCl2 brought to 1250 ml with H2O and bubbled into 1250 ml 2X HBS.Mediawas changed
to IMDM supplemented with 10% heat-inactivated FBS right before transfection and collected in 16 mL of the samemedia. 38 mL of
viral supernatant was ultracentrifuged for 2.5 hours at 25,000 rpm at 4C, and resuspended in 100 ml of D-PBS (GIBCO). Viral titer was
determined by infection of 293FT cells (Thermo Fisher Scientific) at various viral dilutions and percent infection wasmeasured by flow
cytometry analysis of the fluorescent protein expressed.
HSC transplantation
Bone marrow from C57BL/6 mice was extracted by flushing, filtered through a 0.30 mm filter and lineage depleted (Mouse Lineage
depletion kit, Miltenyi Biotec 130-090-858). Cells were stained with EPCR-PE, CD45-APC, CD150-PE/Cy7 and CD48-FITC. DAPI
or LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Thermo Scientific L34963) was used for dead cell exclusion. Sorting of highly
pure E-SLAM HSCs (on a FACSAria IIU, BD Biosciences) and short-term (20 hours) culture was performed as previously described
(Kent et al., 2009). In short, 1000 live EPCR+CD45+CD150+CD48– lineage negative cells were sorted in 100 ml of media: Iscove modi-
fied Dulbecco medium supplemented with 100 U/mL penicillin, 100 mg/mL streptomycin, 1X BIT (bovine serum albumin, insulin,
transferring; purchased as 5X BIT StemCell Technologies), and 104 M b–mercaptoethanol (GIBCO) plus 20 ng/mL interleukin-11
(IL-11; R&D Systems) and 300 ng/mL Steel factor (R&D Systems)). Ultracentrifuged viral supernatant was added aiming for a final
concentration of 2 x 107 IU/ml following the sorting. Each well was used to inject four animals; cells were washed prior to injectinge3 Cell Reports 27, 719–729.e1–e6, April 16, 2019
to remove remaining viral particles. Transplants with the constitutive vector (Figure 2) were performed into lethally irradiated (900 cGy
in two split doses) C57BL/6-CD45.1 animals co-injecting 2 x 105 nucleated whole bonemarrow cells (fromC57BL/6-CD45.1 animals)
per animal. Transplants with the inducible vector (Figures 3A–3C and 4) were performed into sub-lethally irradiated (450 cGy) C57BL/
6-CD45.1; cKit-w41 animals without competitive cells.
LSK re-transplantation
Re-transplants (Figures 3C–3F) were performed following the constitutive vector protocol (into C57BL/6-CD45.1with competitive
dose) using Lin–Sca1+cKit+ (LSK) zsGreen+ cells isolated from transplanted animals. In the case of the re-transplants (Figures
3E–3F), the cells were re-injected the same day they were extracted.
Peripheral blood analysis – constitute shRNA vector
Blood from transplants with the constitutive vector was analyzed starting from 4 weeks after transplantation and every 4 weeks
thereafter. 50–75 ml of blood was extracted from the animals’ tail vein into heparin coated capillary tubes. Red blood cell lysis
was performed using Ammonium Chloride Solution (Stem Cell Technologies). Samples were then stained with B220-APC, CD3-
AF700, CD11b (Mac1)-APC-Cy7, Ly6G-APC-Cy7, CD45.1-PE, and CD45.2-BV421, and analysis was done on an LSR Fortessa
(BD Biosciences). Flow data analysis was performed using FlowJo and statistical analysis using R. All animals used for data analysis
were required to have > 20% donor-derived cells at 16-weeks post-transplant.
Peripheral blood analysis – inducible shRNA vector
For blood analysis from the inducible vector transplants, blood was stained with CD45.1-AlexaFluor700, CD45.2-BV421, CD45R/
B220-APC, Ly-6G-PE, CD11b (Mac-1)-PE-Cy7 and Fixable Viability Dye eFluor 780 (eBioscience) for dead cell exclusion, and the
data acquired using a LSR Fortessa (BD Biosciences). Animals were analyzed from 2 days after doxycycline administration, as indi-
cated in the Figures 3B and 3C. Flow data analysis was performed using FlowJo and plotting and statistical analysis using R.
Peripheral blood analysis – re-transplantations
For re-transplanted animals, blood was stained as for the inducible shRNA vector-transplanted animals, and analyzed at 3 weeks
post re-transplant, as indicated in Figure 3F. Data was acquired using a LSR Fortessa (BD Biosciences) and FlowJo and R were
used for data analysis.
Bone marrow cell isolation and analysis
Bone marrow was isolated from the femurs of euthanized animals at various time points following transplantation. Whole bone
marrow was extracted by flushing and was filtered through a 0.3 mm filter. To obtain progenitor populations, 5 3 107 bone marrow
cells were lineage depleted (Mouse Lineage depletion kit, Miltenyi Biotec 130-090-858). Cells were stained with FcgR-BUV395,
CD34-Biotin-Streptavidin-PE, CD45.1-AF700, CD45.2-V500 or BV510, cKit-APC, Flt3-BV421, IL7Ra-PE-Cy7, Sca1-BV605. Fixable
Viability Dye eFluor780 (eBioscience) was used for dead cell exclusion, and analysis was performed on a FACSAria IIU (BD Biosci-
ences). For analysis of differentiated populations, red blood cell lysis was performed on whole bone marrow using ACK Lysing Buffer
(Thermo Fisher Scientific). Remaining cells were then stained with B220-APC, CD3-AF700, CD11b (Mac1)-APC-Cy7, Ly6G-APC-
Cy7, CD45.1-PE, and CD45.2-BV421, and analysis was done on a FACSAria IIU (BD Biosciences). Flow data analysis was performed
using FlowJo and plotting and statistical analysis using R.
TMRM staining and analysis
For Tetramethylrhodamine, Methyl Ester, Perchlorate (TMRM, Thermo Fisher Scientific, Cat no: T668) analysis, freshly isolated bone
marrowwas incubated in TMRM (20 nM) andVerapamil (50 mM) for exactly 30min at 37C, thenwashed and depleted of differentiated
cell types as described above. Lineage depleted cells were stained with Ly-6A/E(Sca-1)-PerCPCy5.5, CD117(cKit)-APC, CD34-
AF700, CD16/32 (FcgR)-BUV395, CD48-BV421,CD150-PE-Cy7 and analyzed in a FACSARIA IIU (BDBioscience). Flow data analysis
wasperformedusingFlowJo.Relative TMRMfor each indicatedpopulationwas calculatedbynormalizing theTMRMgeometricmean
intensity in that population of interest by the TMRM level of all the stem and progenitor cells – LSK and Lin– Sca1– cKit+ together, to
control for inter animal differences in TMRM signal. Plotting and statistical analysis was performed using R.
lncRNA knockdown analysis
Knockdownmeasurements were performed after inducing shRNA expression for 48h in clonal cell lines selected for uniform zsGreen
induction. We performed each experiment with at least 3 independent clonal cell lines for each shRNA. For all lncRNAs knockdown
efficiency was assessed in MLL-AF9;NRASG12D AML cells (RN2) (Zuber et al., 2011), with the exception of lnc6689 which was as-
sessed in A20 cells. RNA was extracted using the RNeasy Mini Kit (QIAGEN), including treatment with the DNase Set (QIAGEN).
Reverse transcription was performed using Superscript III (ThermoFisher Scientific), with 4 mg of RNA and 1 ml of 50 mM oligo(dT)
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(ThermoFisher Scientific) was used for qPCR. Primer pair efficiency was assessed using serial dilutions of cDNA from untreated RN2
or A20 cells, and melting curves were examined to ensure the presence of only one amplicon. Gapdh was used as a housekeeping
normalization control in the delta-delta-Ct analysis.
Subcellular Fractionation
Subcellular fractionation of MLL-AF9;NRASG12D AML cells (RN2) was performed as previously published (Gagnon et al., 2014). In
brief, 2 x 107 cells were split in two equal aliquots, one for total RNA isolation and one for cellular fractionation. For fractionation, cells
were washed in ice-cold 1XPBS and incubated on ice for 10min in 380 ml of ice-cold Hypotonic Lysis Buffer, HLB, (10mMTris pH 7.5,
10 mM NaCl, 3 mM MgCl2, 0.3% Igepal CA-630 (SIGMA-ALDRICH) and 10% glycerol) supplemented with 100 U of SUPERase-In
RNase Inhibitor (ThermoFisher Scientific). The sample was centrifuged at 1,000 g at 4C for 3 min. The supernatant (cytoplasmic
fraction) wasmixed with 1mL of RNA Precipitation Solution, RPS, (0.5 mL 3M sodium acetate pH 5.5 and 9.5 mL ethanol) and stored
at20C for at least 1 hour. The pellet (semi-pure nuclei) waswashed three timeswith 1mL of ice-cold HBL and resuspended in 1mL
of Trizol LS (ThermoFisher Scientific). The cytoplasmic fractions (in RPS) was vortexed for 30 s and then centrifuged at 18,000 g at
4C for 15min. The pellet waswashed in ice-cold 70% (vol/vol) ethanol and resuspended in 1mL of Trizol LS. RNA from either fraction
or from the total sample (in Trizol) was extracted by adding 200 ml of Chloroform (SIGMA-ALDRICH), mixing and incubating at room
temperature for 10 min. The phases were subsequently separated by centrifugation at 18,000 g at room temperature for 10 min.
An equal volume of 70% (vol/vol) ethanol was added to the aqueous phase and RNA was isolated using the RNeasy Mini Kit
(QIAGEN), including DNase treatment (QIAGEN), performed according to manufacturer’s instructions. The RNA was eluted in
30 ml of Nuclease-free water. Reverse transcriptionwas performed using SuperScript III (ThermoFisher Scientific) as described above
but using equal volumes of RNA solution from each fraction sample (nuclear, cytoplasmic or total RNA). Two primer pairs were used
for lnc12928, in addition to primers forMalat1 as a nuclear control and Gapdh as a cytoplasmic control. Cytoplasmic enrichment for
each primer pair was calculated as the 2-(Cytoplasmic Ct – Total Ct). The nuclear enrichment was calculated accordingly. This does not
provide an absolute measurement of the proportion of lncRNA in each fraction but rather allows one to compare the enrichment
in each fraction to the known controls.
Single molecule RNA FISH
SmRNA FISH probes were ordered from Stellaris conjugated to Quasar 570 Dye.Malat1 andGapdhmouse controls were selected
from the ShipReady Stellaris probe sets. The protocol was performed according tomanufacturer’s instructions for cells in suspension
(Biosearch Technologies). 5 3 106 cells were washed in 1 mL of 1X PBS and the pellet was fixed in 1 mL of Fixation Buffer (3.7%
formaldehyde in 1X PBS) at room temperature for 10 min. The fixed cells were washed three times with 1X PBS and then permea-
bilized at 4C for at least 1 hour using 70% (vol/vol) ethanol. 500 ml of fixed/permeabilized cells werewashed in 500 ml ofWashBuffer A
(10% formamide in 1X Stellaris Wash Buffer A) before incubating in 100 ml of Hybridization Buffer (10% formamide in Stellaris
Hybridization Buffer) containing 125 nM probe at 37C in the dark overnight. The sample was centrifuged to pellet the cells and
50% of the Hybridization Buffer was removed. The pellet was then washed in Wash Buffer A and incubated in the dark at 37C
for 30 min with 500 ml of this same buffer. The nuclei were stained with NucBlue Fixed Cell Stain (ThermoFisher Scientific), the cells
were washed with Stellaris Wash Buffer B and seeded on a clean glass microscope slide in one drop of ProLong Diamond Antifade
Mountant (ThermoFisher Scientific). The cells were imaged in a Nikon TE2000Widefield invertedmicroscope. Z stackswere acquired
by sampling every 0.3 mm. For subcellular localization analysis of the lnc12928 probe, the nuclear or cytoplasmic localization of the
signal was established in the Z stacks where the smFISH was detected. The fraction of cytoplasmic or nuclear signal per cell was
calculated.
50-/30-RACE
50-/30-rapid amplification of cDNA ends (RACE) of MLL-AF9;NRASG12D AML cells (RN2) and lineage-depleted murine bone marrow
progenitor populations (Mouse Lineage depletion kit, Miltenyi Biotec 130-090-858) was performed according to manufacturer’s in-
structions (SMARTer RACE 50/30 Kit, Clontech Laboratories, lnc 634858). 4 primers were designed for each 50- and 30-RACE PCR
according to Section IV of the SMARTer RACE 50/30 Kit User Manual. All primers were used on AML cells, and subsequently the
ones producing the longest insert were used in lineage-depleted primary cells. Total RNA was isolated using the RNeasy Mini Kit
(QIAGEN), including DNase treatment (QIAGEN), and the RNA quality was assessed evaluating the RNA integrity number (RIN)
(Agilent 2100 BioAnalyzer, Agilent Technologies), which were always above 9. RNA samples with an RNA integrity number less
than 7 should be discarded. In brief, 1 mg of total RNA was converted into 50-/30-RACE-Ready first-strand cDNA using Universal
50-/30-CDS Primer A, SMARTScribe Reverse Transcriptase (RT) and, for the 50-RACE cDNA synthesis reaction, the SMARTer II A
Oligonucleotide as an extended template for the SMARTScribe RT. 2.5 mL of the resulted 50-/30-RACE-Ready cDNA samples
were used to generate 50 and 30 cDNA fragments in PCR reactions combining them with SeqAmp DNA Polymerase and the gene-
specific primers. The PCR reaction was performed running 30 cycles of PCR Program 2 described in Section VI of the SMARTer
RACE 50/30 Kit User Manual. RACE products were then cloned into the linearized pRACE vector using the In-Fusion HD Cloning
Kit included in the SMARTer RACE 50/30 Kit. In order to determine the presence of RACE insert of interest, the DNA was analyzed
by restriction digest with EcoRI and HindIII which flank the cloning site. The clones containing the largest gene-specific inserts
were sequenced with M13 primers. The quality of the sanger reads was analyzed manually. Subsequently, sequences were mappede5 Cell Reports 27, 719–729.e1–e6, April 16, 2019
to the mm10 genome with bwa. The 50 end of the 30-RACE products and the 30 end of the 50-RACE products only extended to the
primer used in the reaction. All the lncRNA 50 and 30 ends are represented for each sample.
RNaseq of Spehd-depleted progenitors
LSK and CMP populations were sorted from the bone marrow isolated from transplanted mice as described for bone marrow anal-
ysis. RNaseq libraries were prepared as previously described (Dela´s et al., 2017). In brief, RNA was extracted using the NucleoSpin
RNA XS Kit (Machery Nagel). cDNA and libraries were prepared using the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing
(Clontech), SeqAmp DNA Polymerase (Clontech), and Low Input Library Prep Kit (Clontech). Samples were pooled and run on a
HiSeq 4000.
Spehd-depleted progenitors RNaseq data processing
RNaseq libraries were mapped with STAR aligner (Dobin et al., 2013) against the mm10 mouse genome assembly using default pa-
rameters. Duplicate alignments were removed from the resulting BAM files with Picard (http://broadinstitute.github.io/picard).
HTSeq-count (Anders et al., 2015) was used to calculate gene counts and subsequently input them into DESeq2 (Love et al.,
2014) for quality control analysis, size normalization and variance dispersion corrections. For functional annotation analysis, DESeq2
was used to calculate differentially expressed genes (FDR < 0.05). Significantly downregulated or upregulated genes in CMPs upon
lncRNA knockdown were used independently as input for DAVID 6.7 (Huang et al., 2009). The categories shown are the result of
performing Functional Annotation clustering for each category (Gene Ontology Biological Process, GO Molecular Function, GO
Cellular Compartment of KEGG). Terms with Bonferroni-corrected p value < 0.05 for the first 5 clusters are represented.
QUANTIFICATION AND STATISTICAL ANALYSIS
Specific data analysis workflows, as well as parameters such as center, error bars and significance are described in the Results,
Figure legends and STAR Methods sections. Plotting and statistical analyses were performed in R version 3.4.4 (2018-03-15). For
RNaseq analysis, default parameters were used in all software unless otherwise specified. The version details were as follows:
STAR aligner version 2.5.2a, Picard tools 1.131, ‘HTSeq’ framework, version 0.7.2. used with GENCODE vM11 transcriptome,
DESeq2_1.16.1.
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